Señales en vivo de 4552.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:15):

Stats
Volumen de hoy	800 300
Volumen promedio	720 063
Capitalización de mercado	99.47B
EPS	¥0 ( 2024-01-25 )
Próxima fecha de ganancias	( ¥16.69 ) 2024-05-08
Last Dividend	¥10.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	18.62
ATR14	¥0.642 (0.08%)

Volumen Correlación

Largo: -0.14 (neutral)

Corto: 0.13 (neutral)

Signal:(54.951) Neutral

JCR Pharmaceuticals Co., Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

JCR Pharmaceuticals Co., Correlación - Moneda/Commodity

-0.36
( neutral )

-0.33
( neutral )

-0.31
( neutral )

-0.24
( neutral )

-0.16
( neutral )

0.32
( neutral )

JCR Pharmaceuticals Co., Finanzas

Annual	2022
Ingresos:	¥34.34B
Beneficio Bruto:	¥25.46B (74.13 %)
EPS:	¥30.34

FY	2022
Ingresos:	¥34.34B
Beneficio Bruto:	¥25.46B (74.13 %)
EPS:	¥30.34

FY	2022
Ingresos:	¥51.08B
Beneficio Bruto:	¥40.62B (79.52 %)
EPS:	¥117.26

FY	2021
Ingresos:	¥30.09B
Beneficio Bruto:	¥22.27B (74.03 %)
EPS:	¥55.81

Financial Reports:

No articles found.

JCR Pharmaceuticals Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥10.00 (N/A)	¥0 (N/A)	¥10.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

JCR Pharmaceuticals Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.40 - Stable (12.03%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.250	2007-09-25
Last Dividend	¥10.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	30	--
Total Paid Out	¥100.88	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.40
Div. Directional Score	7.52	--

Next Divdend (Est)
(2024-09-30)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.56

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8233.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
7607.T	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
6804.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6145.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4880.T	Ex Dividend Junior	2023-10-30	Insufficient data to determine frequency	0.00%
4058.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3280.T	Ex Dividend Junior	2024-02-28	Semi-Annually	0.00%
2311.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
9262.T	Ex Dividend Junior	2024-07-30	Annually	0.00%
8011.T	Ex Dividend Junior	2024-02-28	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.130	1.500	7.41	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0522	1.200	8.26	9.91	[0 - 0.3]
returnOnEquityTTM	0.0987	1.500	-0.0142	-0.0213	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.801	0.800	6.00	4.80	[1 - 3]
quickRatioTTM	1.084	0.800	8.33	6.67	[0.8 - 2.5]
cashRatioTTM	0.573	1.500	7.93	10.00	[0.2 - 2]
debtRatioTTM	0.227	-1.500	6.22	-9.33	[0 - 0.6]
interestCoverageTTM	105.82	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.419	-1.500	8.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.748	1.000	0.861	0.861	[0.2 - 0.8]
operatingProfitMarginTTM	0.189	1.000	8.21	8.21	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.242	1.000	9.77	9.77	[0.2 - 2]
assetTurnoverTTM	0.402	0.800	-0.650	-0.520	[0.5 - 2]
Total Score				10.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.54	1.000	8.23	0	[1 - 100]
returnOnEquityTTM	0.0987	2.50	-0.00912	-0.0213	[0.1 - 1.5]
freeCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.51	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.168	1.500	-2.21	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.136	1.000	9.10	0	[0.1 - 0.5]
Total Score				4.40

JCR Pharmaceuticals Co.,

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.